CLINUVEL implements strategic reorganisation to refocus on U.S. markets

CLINUVEL Pharmaceuticals announced a strategic reorganisation effective January 1, 2027, relocating its corporate headquarters from Australia to the United States and reducing its global workforce by 10-20%. The restructuring aims to strengthen U.S. regulatory engagement, focus operations on the U.S. pharmaceutical market, and unlock deeper capital pools from U.S. investors who prefer U.S.-listed companies. The move is driven by the company's recognition that U.S.-listed specialty pharma companies command higher valuation multiples and that over 66% of its shareholder base is already foreign investors.